R&D Big promises, hard work: What 2026 will demand from pharma Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.
Market Access Nine for 2023, part one: a reflection on inflection The Roman god Janus, as we are frequently reminded in January, was two faced and able to look forward to the coming year and backward to reflect on the past one.
News Servier snaps up cancer biotech Day One in $2.5bn deal Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.